Weight Loss
Menopause
menu-close
WHAT WE TREAT
Weight loss
icon
Menopause
icon
ACCOUNT
Log in
icon
OVERVIEW
Weight loss overview
icon
TREATMENTS
Explore all options
Explore all options
icon
Mounjaro
Mounjaro
Lose up to 23% body weight
icon
Wegovy
Wegovy
Lose up to 21% body weight
icon
Saxenda
Saxenda
Lose up to 10% body weight
icon
Orlos
Orlos
Lose up to 8% body weight
icon
PROGRAMME
How it works
How it works
icon
App
App
icon
ABOUT
Results
icon
Experts
icon
RESOURCES
Guides & tips
icon
ACCOUNT
Log in
icon
GET IN TOUCH
020 3912 9885
Mon-Fri 9:00-17:30
icon
OUR CLINIC
Menopause overview
icon
Pricing
icon
Specialists
icon
TREATMENT PLANS
Hormone replacement therapy
icon
Testosterone treatment
icon
Cognitive behavioural therapy
icon
Vaginal treatments
icon
BLOOD TESTS
Women's midlife (MOT) blood test
icon
Check your HRT and testosterone test
icon
Start testosterone blood test
icon
WHAT WE TREAT
Skincare
New
icon
Perimenopause
icon
Menopause
icon
ADHD and menopause
icon
Premenstrual Dysphoric Disorder (PMDD)
icon
LEARN
Guides
icon
Treatments
icon
ACCOUNT
Log in
icon
SUPPORT
FAQ
icon
Home/Guides & Tips/Weight loss/

Retatrutide results

Retatrutide results: Real data vs online hype

Doctors can’t prescribe retatrutide just yet. But here’s what we do know about weight loss results from clinical trials.

clinician image

Medically reviewed by Dr Earim Chaudry (MBBS)

Written by Roj Helin Parlakyildiz (MPharm)

iconUpdated 12th December 2025
Research-Based Guide

Retatrutide is being called the “next generation” weight loss injection. But what do the real results show so far?

Retatrutide is still in clinical testing, so no one can prescribe it yet. The early data has caught attention because participants in trials lost more weight than those on other medications like Wegovy or Mounjaro.

Below, we look at the verified trial results, what to expect in the first month, and why online “before and after” posts aren’t reliable evidence.

Key Takeaways

  • Retatrutide achieved up to 28.7% average weight loss in phase 3 trials, higher than currently available treatments
  • Weight loss begins early, with measurable changes within the first month
  • The medication is still in clinical trials and not approved for prescription use anywhere
  • Online sellers and influencer claims are unreliable. Buying retatrutide outside trials is illegal and dangerous
  • Mounjaro, Wegovy, and orlistat are approved options available through licensed providers

Retatrutide weight loss results: Phase 3 trials

The most up-to-date retatrutide weight loss results come from the first phase 3 clinical trial, TRIUMPH-4.

The trial included 445 adults with obesity (or overweight) and knee osteoarthritis. Participants received weekly injections for 68 weeks, with different dose groups compared to a placebo.

Average weight change at 68 weeks

Group
Retatrutide 9 mg
Retatrutide 12 mg
Placebo
Average weight loss results
26.4%
28.7%
2.1%

People on the highest dose lost nearly 29% of their body weight after 68 weeks. That's more than one-quarter of total body weight on average, the highest seen in any obesity treatment trial to date.

For comparison, the new 7.2mg dose of Wegovy (semaglutide) led to an average loss of 20.7% after 72 weeks, while Mounjaro (tirzepatide) trials reported around 22.5%.

Earlier Phase 2 results

Before the Phase 3 data, a Phase 2 trial with 338 adults showed promising results at 48 weeks. The trial included adults who had a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition.

Group
Retatrutide 1 mg
Retatrutide 4 mg
Retatrutide 8 mg
Retatrutide 12 mg
Placebo
Average weight loss results
8.7%
17.1%
22.8%
24.2%
2.1%

The Phase 3 results confirm and exceed these earlier findings, demonstrating consistent and substantial weight loss across trials.

Retatrutide 1-month results: What to expect early on

Early weight loss with retatrutide begins quickly. In the phase 2 study, participants started to see measurable changes within four weeks of treatment.

By week four, the average weight loss ranged from 2% to 5%, depending on the dose. This early change was similar to what’s seen in the first month of other weight loss injections like Wegovy.

Retatrutide helps with weight loss by mimicking three natural hormones (GLP-1, GIP and glucagon). These hormones work together to reduce hunger, slow digestion and increase the body’s use of stored fat.

Don't wait to hit your health goals
Retatrutide isn’t available yet, but Wegovy and Mounjaro are already helping people lose weight. Start your journey today with proven treatments and support that sticks.
icon
Science backed programme
icon
Personalised support
icon
Trusted by 100k customers across the UK

Other health effects seen in trials

Besides weight loss, trial participants saw improvements in:

  • Blood sugar control (lower HbA1c levels)
  • Blood pressure and cholesterol
  • Liver fat reduction, which may help prevent fatty liver disease

These benefits were seen across doses but were strongest in higher-dose groups.

The early signals are encouraging, but we still need more evidence. Phase 3 clinical trials will help confirm the longer-term benefits and safety.

The risks of buying retatrutide online

Retatrutide is not yet approved for use in the UK. Clinical trials are ongoing, and the medication is only available to people taking part in those studies. Anyone claiming to use retatrutide outside a clinical trial cannot know for certain what they are taking.

On social media platforms like TikTok, you may see bodybuilders or gym-goers claiming to use retatrutide to “cut” or speed up results after a bulking phase (we cover this in more detail in our guide on retatrutide and bodybuilding).

These claims are unlikely to be true. People in those groups would not qualify for current clinical trials.

So if they are using something labelled as retatrutide, it has almost certainly been bought from illegal or unregulated sellers. It is illegal in the UK to sell retatrutide for human use as the drug has not yet been approved.

When you see “retatrutide results” online, keep these signs of hype in mind:

  • Links to sellers or product pages claiming to offer retatrutide, even if labelled “for research only.” These are not authorised for human use.
  • Payments through WhatsApp, Telegram or cryptocurrency, which are common signs of unregulated sales.
  • Discount codes or promotional offers used to encourage purchase or use of an unapproved product.
  • Videos or posts suggesting retatrutide sales are legal in the UK. The medicine is still unapproved and cannot be prescribed.
  • Extreme diet advice or rapid-weight-loss claims that make progress look faster than it really is.
  • Before-and-after photos that look exaggerated, often using lighting or filters.
  • Influencers discussing combinations with other drugs, such as tirzepatide or steroids, which makes any results unreliable.

If you come across claims to sell “research peptides” or “retatrutide vials”, avoid them as they could be dangerous.

For verified information on safe and legal access, see our guide on where to buy retatrutide.

Retatrutide phase 3 results: What’s next?

Retatrutide is being studied in large phase 3 clinical trials known as the TRIUMPH studies, led by Eli Lilly. The first results are in. In December 2025, the TRIUMPH-4 trial showed retatrutide delivered 28.7% average weight loss at 68 weeks, along with significant improvements in knee pain.

Seven more TRIUMPH trials are expected to complete throughout 2026. These are testing retatrutide for weight management and related health conditions like type 2 diabetes and sleep apnoea.

If the remaining results confirm safety and effectiveness, retatrutide will then be reviewed by regulators such as the MHRA in the UK before it can be approved for prescription use. Approval would not be expected before mid-2026 at the earliest. Until that happens, it remains unavailable in the UK.

Is retatrutide available in the UK? Safer options now

No, retatrutide is not available or licensed in the UK yet.

If you’re considering weight-loss medication, safe and approved alternatives include:

  • Wegovy weight loss injections
  • Mounjaro weight loss injections
  • Orlistat weight loss capsules

You can see how these options compare and review real Voy weight loss results.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
FAQ

Retatrutide results: FAQ

Dr Earim Chaudry, MBBS

Continue reading

  • Retatrutide vs Tirzepatide & Semaglutide
  • Retatrutide side effects
  • Retatrutide vs Ozempic
  • Retatrutide vs Wegovy
  • Retatrutide and NHS
  • Retatrutide and alcohol
  • Retatrutide and PCOS
  • Retatrutide vs Mounjaro
  • Retatrutide vs Mazdutide
DisclaimerAt Voy, we ensure that everything you read in our blog is medically reviewed and approved. However, the information provided is not meant to replace professional medical advice, diagnosis, or treatment. It should not be relied upon for specific medical advice.
References
icon¹

Clinical Trial: Retatrutide (LY3437943) in Adults with Obesity or Overweight (TRIUMPH-1).” Eli Lilly Clinical Trials Registryscribble-underline, https://trials.lilly.com/en-US/trial/405675. Accessed 27 Oct. 2025.

icon²

Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Eli Lilly and Companyscribble-underline, 11 Dec. 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average.

icon³

Jastreboff, Ania M., et al. “Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” The New England Journal of Medicinescribble-underline, vol. 389, no. 6, 10 Aug. 2023, pp. 514–526, https://www.nejm.org/doi/10.1056/NEJMoa2301972.

icon⁴

“Lilly’s SURMOUNT-1 Results Published in The New England Journal of Medicinescribble-underline.” Eli Lilly and Companyscribble-underline, 4 June 2022, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine.

icon⁵

Wilding, John P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicinescribble-underline, vol. 384, no. 11, 18 Mar. 2021, pp. 989–1002, https://www.nejm.org/doi/full/10.1056/NEJMoa2032183.

icon⁶

“Wegovy: A New Weight-Loss Option for Obesity and Diabetes.” Applied Clinical Trialsscribble-underline, 12 June 2023, https://www.appliedclinicaltrialsonline.com/view/wegovy-weight-loss-obesity-diabetes.

icon⁷

“Weekly Triple Hormone Receptor Agonist Retatrutide Improves Body Weight and Glycaemic Control in Adults with Type 2 Diabetes.” Nature Medicinescribble-underline, vol. 30, 2024, pp. 1421–1431, https://www.nature.com/articles/s41591-024-03018-2.

Take the first step towards weight loss that lasts.

card-image
Weight Loss
Retatrutide benefits
Discover early research on retatrutide benefits — from major weight loss and fat reduction to improved heart, liver, and metabolic health.
card-image
Weight Loss
Mazdutide vs semaglutide: What’s the difference?
Mazdutide is a new weight loss injection approved in China. Here’s how it might compare to semaglutide, the active ingredient in Wegovy and Ozempic.
card-image
Weight Loss
Orforglipron vs tirzepatide
Here’s how the new weight loss pill orforglipron compares to Mounjaro.
Have a question?
phone icon
020 3912 9885Monday - Friday 9am - 5pm
support icon
help@joinvoy.comWe aim to reply in 24hrs
email icon
press@joinvoy.comPress & media inquiries
Our services are not intended for use in a medical emergency. If you need urgent medical attention, please call 111 or 999.

Programme

  • How it works
  • Treatments
  • Coaching
  • The Voy App

Voy

  • Experts
  • Results

Legal

  • Privacy policy
  • Terms & Conditions
  • Terms of Sale
  • Complaints

Get help

  • Help Centre (FAQ)
facebooktwitterinstagram
Copyright 2025 Voy. All rights reserved.
Pharmacies: Manual PharmacySuperintendent Pharmacist: Vinisha KandaGPhC Registration: 2203475
registered pharmacycqc ratingcpd member